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Abstract: African swine fever (ASF), a disease of obligatory declaration to the World Organization for Animal Health
(OIE), has contributed to poverty and underdevelopment of affected areas. The presence of ASF has been
historically neglected in Africa, contributing to its uncontrolled expansion and favouring its spread to continental
Europe on at least three occasions, the last one in 2007 through the Republic of Georgia. Since then, African swine
fever virus (ASFV) has spread to neighbouring countries, reaching the European Union in 2014, China in the
summer of 2018 and spreading through Southeast Asia becoming a global problem. Lack of available vaccines
against ASF makes its control even more difficult, representing today the number one threat for the swine industry
worldwide and negatively affecting the global commerce equilibrium.
Main body: In this review, we intend to put in perspective the reality of ASF vaccination today, taking into account
that investment into ASF vaccine development has been traditionally unattractive, overall since ASF-free areas with
large swine industries applied a non-vaccination policy for diseases listed by the OIE. The dramatic situation
suffered in Asia and the increasing threat that ASF represents for wealthy countries with large swine industries, has
dramatically changed the perspective that both private and public bodies have about ASF vaccinology, although
this is controversial. The feasibility of modifying the ASFV genome has led to safe and efficacious experimental
recombinant live attenuated viruses (LAVs). The main challenge today will be confirming the safety and efficacy of
these technologies in the field, accelerating transfer to the industry for official registration and commercialization.
The complexity of ASFV, together with the lack of knowledge about the mechanisms involved in protection and
the specific antigens involved in it, requires further investment in research and development. Although far from the
efficacy achieved by LAVs, subunit vaccines are the optimal choice for the future. If the world can wait for them or
not is a contentious issue.
Conclusion: Despite their inherent disadvantages, LAVs will be the first technology to reach the market, while
subunit vaccines will need much further research to become a successful commercial reality.
Keywords: African swine fever (ASF), African swine fever virus (ASFV), Live attenuated virus (LAV), Subunit vaccines,
Antibodies, Cytotoxic CD8+ T-cells (CTLs), Protection, Biosafety
Background
African swine fever (ASF) is a swine hemorrhagic viral
disease that is of mandatory declaration to the World
Organization for Animal Health (OIE). The disease is
caused by African swine fever virus (ASFV), a large
nucleocytoplasmic virus that contains a double-stranded
170–190 kb DNA genome, encoding 151–167 open
reading frames (ORFs) [1]. The ASFV virion is a com-
plex multi-enveloped and multi icosahedral particle con-
taining at least 68 different structural viral polypeptides
and 21 cellular proteins and possess a much more com-
plex structure than previously believed [1–3]. ASFV rep-
licates predominantly in mononuclear-phagocytic cells
(monocytes and macrophages), which play a front-line
role in activating and orchestrating the innate and
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adaptive host responses. During infection, ASFV express
multiple proteins that subverts several host pathways in
order to ensure efficient virus replication in vivo [4].
ASF was described for the first time in Kenya in 1921 as
a lethal hemorrhagic disease affecting the first European
imported domestic pigs and being maintained asymp-
tomatically in a sylvatic cycle between ticks of the genus
Ornithodoros and warthogs (Phacochoerus spp.), acting
as long-term carriers and reservoirs of ASFV [5]. The
complex live cycle of ASFV in this region explains the
actual presence of more than 24 different ASFV geno-
types, classification based on the sequence of B646L, en-
coding p72, the major capsid protein [6]. Outside Africa,
only genotypes I and II have been found and both do-
mestic pigs and wild boars (both being Sus scrofa), are
equally susceptible to the disease [7]. When introduced
into disease-free regions or domestic pig populations,
the disease predominantly shows acute forms with high
mortality rates up to 100%. After several years of ASFV
presence in endemic areas, mortality rates decline due to
virus adaptation to the hosts and infected individuals
show subacute forms of the disease or even no clinical
signs, complicating even more its detection and eradica-
tion, as described in the Iberian Peninsula [8]. ASFV can
spread into neighboring areas carried by free-ranging in-
fected wild animals but it can also emerge into new dis-
tant areas by the illegal transport of infected pigs, the
use of contaminated pork or pork products for feeding
pigs, or even fomites such as equipment (boots, trucks,
etc.) not properly disinfected. Once established, the virus
disseminates via oral-nasal routes by direct contact be-
tween infected and non-infected individuals or with con-
taminated products [9]. Unfortunately, ASFV is one of
the most resistant viruses to chemical and physical in-
activation, therefore complicating the tasks of disinfec-
tion. Transcontinental spread of ASFV from Africa first
occurred in two consecutive waves: 1957 and 1960,
when genotype I viruses emerged in Spain and Portugal,
where it became endemic and spreading to other Euro-
pean countries, South America and the Caribbean. The
eradication campaign from the European Continent
lasted more than 30 years and provoked enormous eco-
nomic losses in affected countries [8]. The complex
ASFV epidemiological situation above described in Af-
rica, together with the absolute lack of intervention from
the rest of the world, facilitated the exportation of the
virus again to Europe, catching us totally off guard and
unprepared. Thus, barely 10 years after declaring the
continental European Union (EU) free of ASF, a second
transcontinental outbreak occurred in 2007, when geno-
type II ASFV from Eastern Africa was first detected in
Georgia [10]. From the Caucasus, and with the involve-
ment of wild boars in the spread, ASFV broke first into
Eastern Europe and Baltic Countries, reaching the first
EU countries in 2014. In August–September 2018, ASFV
was declared in China, the country that raises half of the
world’s pig population and a year and a half later the
situation can be described as a global epidemic threating
global swine production [11].
The need of a vaccine for ASFV
Lack of vaccines against ASF leaves the control of the
disease to an efficient and rapid diagnosis and the cul-
ling of infected and exposed animals (www.oie.int). This
strategy has been demonstrated as inefficient in coun-
tries with limited resources, incapable of implementing
fair policies of compensation and ASF control.
Lack of efficient treatments or vaccines against ASF com-
plicate ASF control even more. Development of vaccines
against ASF has been historically unattractive for the indus-
try. On one hand, ASF remained endemic almost exclu-
sively in Africa, and on the other hand, ASF-free countries
with developed swine industries apply a non-vaccination
policy for diseases of obligatory declaration to the OIE
(www.oie.int). Therefore, there is still a lot of work to per-
form to provide safe and efficient vaccines and to guarantee
their optimal application in the field [12]. However, the en-
trance of ASFV in China has totally changed the perception
of ASF vaccinology [13, 14]. Limited resources together
with the complexity of the virus have contributed to
explaining the gaps existing today regarding ASFV infection
and immunity. So far, the precise nature of the host pro-
tective responses has not been fully determined and pro-
tective antigens remain to be identified, hampering the
rational design of vaccines. Despite these limitations, the
few laboratories devoted to work on ASF vaccinology, have
contributed to several seminal findings in the field [15].
Thus, we can confirm today: first, that vaccines against ASF
are not a utopia; second, that LAVs can be a short-medium
term reality to fight the disease, overall in endemic regions
or regions in danger to become endemic; and third, that
subunit vaccines can be a long-term vaccine choice.
Collaborative efforts between academia and industry
should allow the improvement of safety and DIVA properties
(capable to Differentiate Infected from Vaccinated Animals)
of the experimental vaccine prototypes below described. This
should be the beginning of a new era for ASF vaccinology
where continuous collaborative research will be needed to
obtain the safest and most efficient vaccine in the future.
Controlling the virus in Asia and Europe is mandatory for
the swine industry, but controlling ASFV in Africa should be
mandatory for humanity. Even if we do not appeal to hu-
manitarian reasons, we should turn to common sense, since
reducing the epidemiological pressure of ASFV in Africa
should diminish the risk of exportation of new ASFV strains
in the future. Collaboration between researchers in the field,
private companies, governmental bodies and international
organisms such as the OIE and the Food and Agriculture
Bosch-Camós et al. Porcine Health Management            (2020) 6:17 Page 2 of 14
Organization of the United Nations (FAO) is necessary if we
are willing to succeed in controlling ASF, today the number
one global threat for animal health.
Classical vaccines: understanding the mechanisms involved
in protection
Classical vaccines based on inactivated ASFV, independ-
ently of the inactivation method and the adjuvant used,
have proven ineffective [16, 17]. Despite inactivated vac-
cines being very efficient at inducing antibodies, on oc-
casions capable of blocking the virus in fluids, they are
not very efficient at inducing specific cytotoxic CD8+ T-
cells (CTLs) [18], crucial for elimination of virus-
infected cells. Incorporation of new adjuvant formula-
tions and novel and more innocuous inactivation proce-
dures, might contribute to designing efficient inactivated
vaccines in the future [1–3].
LAVs, whether naturally attenuated or adapted to tis-
sue culture, have been used as experimental models to
understand the mechanisms involved in homologous
protection against ASF.
The presence of ASFV-specific CTLs was initially dem-
onstrated using PBMCs from animals surviving the infec-
tion with attenuated viruses [19–21]. More recently, the
CTL activity has been associated to both CD8+ and double
positive CD4+/CD8+ T-lymphocytes, the latter thought to
include memory/effector T cells [22]. The definitive evi-
dence identifying ASFV-specific T-cells as crucial for
ASFV protection came after the demonstration that
in vivo depletion of CD8+ cells abrogated protective im-
munity to ASFV [23]. Today we know that two distinct
phenotypes of porcine CTLs are capable to lyse ASFV-
infected cells: a conventional CD8 single positive, and a
CD4+CD8αβ+ phenotype, both being perforin positive and
showing swine leukocyte antigen I (SLA I)-restricted cyto-
toxicity. Increasing levels of circulating conventional
CD8+ T-lymphocytes have been correlated with the onset
of ASF clinical signs, while CD4/CD8αβ double positive
CTLs were significantly increased in protected pigs [24].
Similarly, passive administration of antibodies or colos-
trum from ASF convalescent pigs, conferred partial pro-
tection against experimental ASFV lethal challenge [25,
26], therefore demonstrating their protective potential.
Nonetheless, 25 years later, the exact mechanisms by
which this partial protection was afforded are not yet fully
understood. While some authors correlated the protection
afforded with the presence of antibody-dependent cell-
mediated cytotoxicity [26], others associated it with the
presence of neutralizing antibodies [27], an issue still con-
troversial today [28]. A third complementary mechanism
of antibody-mediated protection has been postulated [29]
based on studies using sera from pigs surviving the infec-
tion with several hemadsorbing ASFV strains. In these
studies, a direct correlation was observed between the
presence of hemagglutination inhibitory antibodies, the
ability of these antibodies to in vitro inhibit ASFV infec-
tion and the capability of these animals to survive the ex-
perimental challenge with the homologous virulent virus
[30].
In our vision, both an adequate innate immune re-
sponse [31] together with adaptive responses, including
antibodies and CD8+ T cells, will be essential to induce
sterilizing immunity against ASFV.
Despite their enormous efficacy, the use of ASF LAVs as
vaccines in the field is still controversial [12], mainly due
to biosafety concerns related to their inherent infectious
nature. Natural attenuation of ASFV in endemic areas has
complicated its eradication, mainly due to the difficult
identification of chronically infected pigs that might act as
continuous reservoirs [8]. ASFV chronicity paralleled with
a total change of clinical findings [32]. The concomitant
presence of virus and antibodies correlated with the pres-
ence of lesions compatible with immune complex depos-
ition, including necrotic foci in joint swelling [33–35].
Antibody exacerbation phenomenon has been also ob-
served after immunization with inactivated virus and even
after experimental immunization with subunit vaccines
[17, 36–38]. The fine balance existing between the pro-
tective and detrimental role of ASFV-specific antibody re-
sponse needs further investigation, both from the basic
and applied point of view. Understanding the intrinsic
mechanisms explaining the protection and the exacerba-
tion caused by ASFV-specific antibodies is crucial for fu-
ture vaccine designs. Albeit not frequently reported,
natural attenuation of ASFV has been also reported more
recently in the Caucasian region, mostly associated to wild
boars [39, 40]. Experimental infection with some of these
new isolates ratified their attenuation in domestic pigs
[40] and in wild boars [41]. Together with the polemic use
of these ASFV strains as vaccines or as vaccine templates
in the future [12, 41], their presence in nature open new
concerns about the eradication measures today in place,
based on detecting ASFV nucleic acid. The presence of at-
tenuated ASFV isolates in the field deserves deeper studies
and if confirmed, evaluating the additional implementa-
tion of antibody detection methods as performed during
the eradication campaigns in Spain [42]. China, where the
virus has infected more pigs in only 1 year that in its en-
tire history, might parallel the fastest evolution ever re-
corded for ASFV, therefore increasing the risk for the
region to become endemic. What in the short term might
look like a successful exit from the current living drama
could bring long-term consequences for global commerce.
Recombinant LAVs: coming closer to the market
Today the possibility of deleting specific genes using re-
combination technologies [43] or by genome editing using
the CRISPR-Cas9 system [44], opens the possibility of
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obtaining safer LAVs. The main LAVs tested in vivo are
summarized In Table 1, especially remarking those with
potential to protect against the virus currently circulating
in Europe and Asia. Genome manipulation has provided
crucial information about essential and non-essential
ASFV genes involved in replication, viral morphogenesis
and of course, in virus virulence [4, 65].
As a good example for the purpose of this review, deple-
tion of EP402R gene from the non-pathogenic BA71V iso-
late, allowed in vitro identification of CD2v (EP402R
product), as the ASFV hemagglutinin [45]. Unfortunately,
the non-infectious nature of BA71V made the in vivo
characterization of BA71VΔCD2, or any other recombin-
ant virus made on this background impossible [66]. The
first deletion mutant tested in vivo was Δ8-DR, a recom-
binant precisely lacking CD2v, made on the virulent
Malawi Lil-20/1 ASFV strain [46]. Despite its incapability
to bind red blood cells, Δ8-DR was still lethal in vivo,
showing a delay/reduction in viremia kinetics but causing
clinical signs and mortality similar to those caused by the
parental virus. From here, few genes have been identified
as implicated in the virulence of different ASFV virulent
strains: DP71L (NL), B119L (9GL), DP96R (UK), DP148R
and multigene families 360 and 505 (MGF360 &
MGF505) [49–53, 55–57]. Some of these genes have been
also eliminated from Georgia2010, the Genotype II virus
currently circulating in Europe and Asia; deletions that
have caused attenuation and different degrees of homolo-
gous protection in vivo [54, 58]. Interestingly, the con-
comitant elimination of the 9GL and UK from the
Georgia2010 virus resulted in more effective vaccine pro-
totypes than those lacking individual ORFs [59]. Similarly,
recent results published in Science China Life Science,
demonstrate the safety and the efficacy of a new recom-
binant LAV obtained from deleting the already described
MGF360/530 and CD2v virulence factors [64]. It is of cru-
cial relevance for beginners in the field to be aware that
concomitant elimination of ASFV virulence factors does
not always result in better attenuation, on occasions yield-
ing very weak viruses incapable to grow in vivo, or at least
incapable of inducing protective responses. This is the
case for example of a Georgia2010 triple mutant lacking
9GL, UK and NL [61] or a Georgia2010 double mutant
lacking 9GL and MGF360/MGF505 [60]. Likewise, deple-
tion of specific virulence factors from natural LAVs, have
decreased their ability to protect against challenge with
the parental virulent virus [62, 63]. And finally, depletion
of a single gene can result in different phenotypes depend-
ing on the virus strain used, as has been demonstrated for
NL [51], and more recently for CD2v [47, 48]. These ob-
servations are of extreme relevance when rationally de-
signing LAVs against ASFV, since on most occasions they
limit their protection against the parental virulent strain
(homologous virus) but not against heterologous strains.
The definition of homologous and heterologous for ASF
has not been well defined, observing a lack of cross-
protection on occasions between viruses isolated in close
endemic regions and in the same period [30]. Although
useful to understand ASFV evolution, genotyping [6] does
not correlate with protection. On the other hand, serotyp-
ing based on hemadsorbing inhibition assays, seems to
partially explain cross-protection [67], but there is still
much to learn, since protection can be afforded in the ab-
sence of CD2v [48, 62, 63]. Furthermore, viruses with
identical CD2 and lectin behave as heterologous in vivo
[30]. Lack of in vitro correlates for protection leaves ex-
perimental in vivo challenging as the only way to demon-
strate the cross-protective nature of a novel vaccine.
Twenty-five years after its deletion from the non-
pathogenic BA71V [45], the EP402R gene (CD2v) was
deleted from the parental BA71 virulent virus to obtain
BA71ΔCD2 for the completion of in vivo studies [48].
BA71ΔCD2 induced strong humoral and cellular re-
sponses and conferred solid protection against the hom-
ologous virus (BA71) in a dose-dependent manner. For
the first time solid protection was conferred not only
against homologous virus but also against heterologous
viruses such as E75 (Genotype I) or the phylogenetically
more distant Georgia2007/1 strain (Genotype II) cur-
rently circulating in Continental Europe and Asia. Fi-
nally yet importantly, BA71ΔCD2 presents the
additional advantage of being capable of stably growing
in the commercial Cos-1 cell line without needing previ-
ous adaptation. Despite the impressive protective cap-
acity achieved with this experimental vaccine,
BA71ΔCD2 needs further improvement, mainly from
the biosafety point of view. A small proportion of vacci-
nated pigs show short periods of low, albeit detectable
BA71ΔCD2 in both sera and nasal swabs coinciding with
mild fever spikes, but no other ASF-compatible clinical
signs. All animals end up eliminating the virus in the
first 4 weeks after vaccination.
This chapter deserves a closing with unexpected good
news. The specific deletion of the previously uncharac-
terized I177L gene provokes the dramatic attenuation of
the virus and most importantly, confers sterilizing pro-
tection against the virus currently threating our pig in-
dustry [68]. This result clearly demonstrates that the
systematic deletion of each one of the ASFV genes, inde-
pendent of in silico predictions could bring satisfactory
surprises. This is not a question of luck but conversely,
rewards one of the few groups consistently working on
ASFV vaccine discovery, a field with plenty of frustra-
tions that also bring some satisfactions.
Despite their imperfections, LAVs available today con-
fer a level of protection against experimental ASF infec-
tion far better than any other vaccine strategy so far
tested (see the following chapter). Ideal LAVs should
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however accomplish the following requisites before be-
coming a reality in the field:
1) Safety. Experimental LAVs should demonstrate in
the field not only to be efficacious, but also safe for
the vaccinated pigs, for the in-contact animals and
for the environment.
2) DIVA. Vaccinated pigs should ideally induce an
immune response distinguishable from naturally
infected pigs.
3) Biofactory. Vaccines should be produced under
high quality standards and following the policy of
the corresponding regulatory agencies, thus
requiring stable cell lines for producing the LAV at
a large scale.
4) Cross-protection. Cross-protective vaccines could
be useful not only to protect a specific region against
a single virus, but against many different viruses from
the same genotype or from different genotypes
(ideally all), thus covering endemic regions of Africa
where up to 24 genotypes have been described.
5) Wildlife: LAVs formulations compatible with wild-
life immunization campaigns will also be demanded
if willing to control and eradicate ASF. Bait-vaccine
formulations should also demonstrate their safety
and efficacy in field studies.
Vaccines are one of the best human inventions, but
this truth circumscribes exclusively the “good ones”:
those proven efficient, safe and correctly administered in
the field. Balancing the risks and the benefits of imple-
menting each available vaccine, applying scientific cri-
teria and avoiding pre-established interests and
prejudices, should be mandatory in the future.
Antigen discovery and development of subunit vaccines
In order to avoid, or at least diminish, the unwanted side
effects of traditional inactivated and attenuated vaccines,
subunit vaccines arise as an ideal option for the future
development of ASF vaccines [15]. As mentioned above,
little is known about the mechanisms involved in protec-
tion and even less about the antigens responsible of such
protection. To fill these gaps, research from both public
administrations and the private sector should be encour-
aged: from antigen discovery to adjuvant and expression
vector, more research investment is needed to design
the ideal vaccines of the future. Screening of potential
antigenic determinants within the ASFV is a challenging
task due to the complex nature of this virus, encoding
more than 150 ORFs and from which many of them
there is neither expression nor functional data available.
In this section, we collect relevant studies regarding
ASFV antigen discovery as well as significant advances
in the development of subunit vaccines against ASF.
The Yin and the Yang of ASFV-specific antibodies
The ASFV serological determinants determined so far
are listed in Table 2, specifically indicating those capable
of inducing antibody responses after immunization
in vivo. As described above, the presence of neutralizing
antibodies and their potential role in protection is still
today polemic [28]. On the one hand, neutralizing
monoclonal antibodies recognizing the major capsid
protein p72 were described decades ago [76], but no fur-
ther development has been recorded. Similarly, specific
polyclonal antibodies against p54 (encoded by the E183L
ORF) and p72 (B646L) were capable of blocking the
ASFV-attachment to susceptible cells, while antibodies
against p32 (CP204L) inhibited virus internalization,
both mechanisms essential to protect pigs against E75
lethal challenge [27]. Unfortunately, the protection
afforded by p72, p54 and p32 was not reproducible using
other infectious model systems [77], opening new con-
cerns about their relevance in protection and contribut-
ing to feed the controversy still in force, about the
protective role of antibody-mediated neutralization. Due
to the fact that p72, p32 and p54 are among the most
immunogenic structural proteins, they have been in-
cluded in diverse experimental vaccine formulations
aiming to confer protection against several virulent
ASFV isolates, with little if any significant effect [37, 38,
72, 73, 77].
Parallel studies performed aiming to identify ASFV
proteins responsible of inducing hemagglutination in-
hibitory antibodies [30], provided the identification of
CD2v as the ASFV hemagglutinin. Thus, immunization
of pigs with Sf9 insect cells infected with a recombinant
baculovirus encoding the ASFV protein CD2v in the
presence of Freund’s adjuvant, conferred protection
against E75 ASFV challenge. The protection afforded
was dose-dependent and correlated with the presence of
antibodies capable of inhibiting hemagglutination and
the homologous ASFV infection in vitro [29]. This work
has been more recently confirmed by identifying CD2v
and the ASFV lectin as key protective antigens [83],
which could be useful to serotype ASFV [67]. As de-
scribed for p32, p54 and p72, some experimental vaccine
formulations containing CD2v have failed at inducing
solid protection, perhaps reflecting antigenic and patho-
genic differences between the ASFV strains used or in
the vaccine formulations per se [37, 38, 78, 81, 84].
Together with p54, p32 and p72, many other antigens
have been identified by sera from recovered pigs as immu-
nodominant antigens, including the structural polypro-
tein pp62 [80]. Sera from convalescent pigs also recognized
some other structural proteins (A104R, C-type lectin
pEP153R, chaperone pB602L and K78R), non-structural
proteins (RNA reductase, DNA ligase and thymidine kin-
ase) as well as proteins of unknown function and location
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Table 2 ASFV serological immunodeterminants, indicating those described to be recognized by sera from pigs recovered from ASFV
infection (antigenic) or to induce immune responses after in vivo immunization (immunogenic)
Gene name Protein Antigenic Reference Immunogenic Reference
Structural
A104R Histone-like DNA-binding protein Yes [69, 70] Yes [71]
A137R P11.5 – – Yes [72]
B438L p49 – – Yes/Low [73, 74]
B602L p72 chaperone Yes [69, 70] Yes [74, 75]
B646L p72, major capsid protein Yes [27, 69, 76] Yes [71, 72, 77, 78]
CP204L p30 Yes [27, 69] Yes [38, 71–73, 77–79]
CP2475L pp220 – – Yes [72]
CP2475L/partial p37 – – Yes [71]
CP530R pp62 Yes [80] Yes [38, 81]
CP530R/partial p35 – – Yes [37, 78]
CP530R/partial p15 – – Yes [37, 78]
D117L Major transmembrane
protein p17
– – Yes [73]
E183L p54 Yes [27, 69, 70] Yes/Low [37, 71, 73, 77–79]
EP153R C-type lectin – – Yes [73]
EP402R HA/CD2v Yes [82] Yes [71, 73, 78]
K78R p10, DNA-binding Yes [69] – –
KP177R p22 – – Yes/Low [73, 77]
E120R p14.5 – – Low [73]
H108R Inner envelope – – Low [73]
O61R p12 – – Yes [73]
Non-structural
B119L 9GL, virus assembly – – Yes [74]
F334L RNA reductase Yes [69] – –
I215L Ubiquitin conjugating enzyme – – Yes [38]
K196R Thymidine kinase Yes [69] – –
L10L KP177R-related – – Yes [73]
NP419L DNA ligase Yes [69] – –
Uncharacterized
A151R – – – Yes [74]
C129R – – – Yes [38]
C44L – Yes [69] – –
CP312R – Yes [69] Yes [78]
E184L – Yes [69] – –
K145R – Yes [69] – –
K205R – Yes [69, 70, 75] Yes [74]
M448R – – – Yes [38]
Multigene families
MGF110-4 L XP124L – – Yes [38]
MGF110-5 L V82L – – Yes [38]
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(C44L, CP312R, E184L, K145R and K205R) [69, 70, 75, 85].
Unfortunately, the protective efficacy of most of these anti-
gens has not been confirmed.
More recently, immunization of pigs with complex
ASFV-antigen formulations induced specific antibody re-
sponses that allowed the identification of additional anti-
genic determinants. Thus, Babraham syngeneic pigs
immunized with a cocktail of 44 antigens in a DNA-prime
recombinant vaccinia-boosting regime, recognized D117L
as a novel ASFV immunogenic protein [73]. After chal-
lenge with Georgia2007/1, all pigs developed acute ASF,
albeit viral genome levels were significantly reduced in im-
munized pigs in blood and lymphoid tissues. More re-
cently, adenovirus-priming and vaccinia Ankara (MVA)-
boosting regimes using diverse antigen combinations,
allowed the definition of five additional ASFV antigens as
good antibody inducers: MGF110-4 L, MGF110-5 L,
M448R, C129R, I215L [38]. As before, immunization did
not protect pigs from acute ASF (OUR T88/1 challenge)
but reduced the viremia in a proportion of outbred pigs.
Immunization with different cocktails of recombinant
adenoviruses allowed the confirmation of the immuno-
genicity of B602L, K205R-A104R, CP530R, CP2475L and
the extracellular domain of EP402R, identifying for the
first time A151R and B119L as good antibody inducers,
albeit none of the cocktails induced significant protec-
tion against Georgia2007/1 [71, 74, 81]. Immunization
with recombinant adenoviruses encoding: p32, p54,
pp62, p72, and p37 and p150 (mature proteins processed
from the pp220 polyprotein) seemed to afford some pro-
tection depending on the adjuvant used, while other vac-
cine formulations exacerbated the disease [81].
Despite the efforts made, none of these antigen-specific
antibodies have been confirmed to be protective in an un-
arguable manner and we are still far from identifying
ASFV antigens capable to confer solid protection against
Georgia2007/1 challenge and even further from the opti-
mal formulations. In fact, antigenicity and protection do
not concur and, on occasions, and an inverse correlation
has even been demonstrated. This effect has been de-
scribed upon natural and experimental ASFV infection
with LAVs and also after immunization with inactivated
and subunit vaccine formulations [17, 36–38, 81].
The fine balance existing between the protective and
detrimental role of ASFV-specific antibody response
needs further investigation, both from the basic and ap-
plied point of view. Antibodies play a role in protective
immunity against ASFV, although the specific antigens
and/or the way to be targeted are still unknown.
The unknown: ASFV antigens inducing T-cell responses
ASFV vaccinology, as well as traditional veterinary vacci-
nology in general, has focused on triggering antibody re-
sponses, while little attention has been paid to the role
that cellular responses play in protection. This reality
has dramatically changed in recent years, and future vac-
cinologists would have to focus their attention also on
this crucial arm of the immune response. However, few
in vitro studies have centered their attention on identifi-
cation of ASFV proteins inducing CTLs. The antigens so
far recognized by ASFV-specific T-cells, as well as those
described as immunogenic in vivo (capable to induce
specific T-cell responses upon immunization), are listed
in Table 3.
The first ASFV CTL target identified in vitro was pro-
tein p32 [87], followed by the major capsid protein p72
and G1340L [86, 92]. Aiming to maximize the screening
coverage of ASFV antigens, a random plasmid library of
ASFV genomic DNA was generated and expressed in
pig-derived fibroblasts. Sequencing of the clones that
stimulated CD8+ T-cell proliferation revealed that one of
the clones encoded a segment of I329L, a putative ASFV
membrane protein. Notably, this technique allowed the
identification of sequences that were in different reading
frames than any of the known ASFV ORFs [90], indicat-
ing that the proteome of ASFV could be more complex
than previously believed. This hypothesis has been re-
cently supported by the identification of novel ASFV
ORFs by RNA sequencing methods [93].
Despite the unarguable reality of CD8+ T-cells playing
a role in protection, few ASFV antigens have demon-
strated their protective potential (Table 4), still far from
that afforded by LAVs. Today we know that CD2v can
also exhort its protective effects by stimulating the in-
duction of specific CD8+ T-cells [88, 89]. Thus, DNA
immunization with a plasmid encoding p32, p54 and the
extracellular domain of CD2v, fused to ubiquitin aiming
to enhance the CTL responses induced, conferred partial
protection against lethal challenge with E75. The protec-
tion afforded correlated with the induction of specific
CD8+ T-cells recognizing two 9-mer peptides from the
CD2v and in the absence of antibodies [89]. Work per-
formed in our laboratory using DNA immunization has
allowed not only the identification of new protective anti-
gens but has also contributed to dissect the mechanisms
involved in protection. Thus, immunization with a ran-
dom library containing more than 4000 clones encoding
random ASFV genome fragments (excluding the se-
quences encoding p32, p54 and CD2v to avoid competi-
tion) fused to ubiquitin protected 60% of the animals
against E75 lethal challenge. The protection was again
afforded in the absence of detectable specific antibodies
after immunization and correlating with the induction of
ASFV-specific T-cell responses [91] against several anti-
gens, including CP312R [94]. These results clearly demon-
strated the presence of additional protective CD8+ T-cell
determinants within the ASFV genome. These results
highlighted the convenience of formulating vaccines a la
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Table 3 ASFV-specific T-cell determinants, indicating those described to be recognized by PBMCs from pigs recovered from ASFV
infection (antigenic) and those inducing T-cell responses after in vivo immunization (immunogenic)
Gene name Protein Antigenic Reference Immunogenic Reference
Structural
B602L p72 chaperone – – Yes [73]
B646L p72 Yes [38, 86] Yes [38, 71, 73]
CP204L p30 Yes [38, 87] Yes [38, 71, 73]
CP2475L pp220 – – Yes [73]
CP530R pp62 Yes [38] Yes [38, 71, 73]
CP530R/partial p15 – – Yes [37]
D117L – – – Low [73]
E183L p54 – – Yes [71, 73]
E248R Transmembrane myristoylated protein Yes [38] – –
EP153R C-type lectin Yes [88] Yes [73]
EP402R HA/CD2v Yes [88] Yes [73, 89]
H108R Inner envelope – – Low [73]
I239L – Yes [90] – –
K78R p10 Yes [38] No [38]
KP177R p22 Yes [38] Yes [73]
B438L p49 – – Yes [73, 74]
E199L j18L – – Yes [73]
O61R p12 – – Yes [73]
Non-structural
A179L – – – Low [73]
B119L 9GL, virus assembly – – Yes [74]
C475L Poly(A) polymerase Yes [38] – –
C962R DNA primase Yes [38] – –
DP71L Protein phosphatase 1 regulator – – Low [73]
E165R dUTPase Yes [38] Yes [38]
E296R AP endonuclease Yes [38] – –
F1055L Helicase – – Yes [73]
F334L RNA reductase Yes [38] – –
G1211R DNA polymerase – – Yes [73]
G1340L VACV A7 early transcription factor large subunit-like Yes [86] Low [73]
H339R Alpha-NAC binding protein Yes [38] – –
H359L RNA polymerase subunit 3–11 Yes [38] – –
I215L Ubiquitin conjugating enzyme Yes [38] Yes [38]
I329L TLR inhibitor – – Low [73]
NP1450L RNA polymerase subunit 1 – – Yes [73]
NP419L DNA ligase Yes [38] Yes [73]
NP868R mRNA-capping enzyme Yes [38] – –
O174L DNA polymerase X Yes [38] – –
Multigene families
MGF110-1 L – Yes [38] Yes [38]
MGF110-2 L – – – Low [73]
MGF110-4 L XP124L Yes [38] Yes [38]
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carte, encoding not only the appropriate ASFV antigens
but also targeting them to specific antigen presentation
pathways aiming to enhance the induction of protective
responses and avoiding undesired adverse immune re-
sponses after vaccination [36].
More recently, an overlapping peptide library comprising
almost 4000 20-mers peptides overlapping by 10 amino
acids from 133 different ASFV ORFs, was used in in vitro
stimulation protocols using PBMCs from ASFV-
convalescent pigs to identify potential CD8+ T-cell targets
[38]. The specific responses induced were measured in an
IFNγ ELISpot assay, identifying peptides from 38 ASFV
proteins in at least one of the tested pigs, including p72
and p32, but also many other uncharacterized proteins
(Table 3).
Interestingly, immunization with adenoviruses encod-
ing the structural proteins: p32, p54, pp62, p72 and
pp220 in the presence of the ZTS-01 adjuvant induced
lower antibody responses and slightly better protection
(non-statistically significant), than with the BioMize
Table 3 ASFV-specific T-cell determinants, indicating those described to be recognized by PBMCs from pigs recovered from ASFV
infection (antigenic) and those inducing T-cell responses after in vivo immunization (immunogenic) (Continued)
Gene name Protein Antigenic Reference Immunogenic Reference
MGF110-5 L V82L Yes [38] Yes [38]
MGF300-1 L J268L Yes [38] Low [73]
MGF300-2R – – – Low [73]
MGF360-11 L KP362L – – Yes [73]
MGF360-15R – – – Low [73]
MGF360-16R – Yes [38] – –
MGF360-18R – – – Low [73]
MGF360-1 L KP360L – – Yes [73]
MGF505-11 L – Yes [38] – –
MGF505-4R – – – Yes [73]
MGF505-5R A498R Yes [73]
Uncharacterized
285 L – Yes [38] – –
A151R – Yes [38] Yes [38]
B407L – – – Low [73]
C129R – Yes [38] Yes [38]
C257L – Yes [38]
CP312R – Yes [38] Yes [38]
CP312R – – – Yes [31, 91]
D339L – – – Low [73]
DP238L – Yes [38] – –
E120R – – . Low [73]
E146L – Yes [38] Yes [38]
E184L – Yes [38] Yes [38]
EP364R – – – Yes [73]
F317L – – – Yes [73]
I243L – Yes [38] – –
I73R – Yes [38] No [38]
K205R – Yes [38] Yes [73, 74]
L8L – Yes [38] – –
L10L – Yes [38] Low [38, 73]
M1249L – Yes [38] Low [73]
M448R – Yes [38] Yes [38]
Complement (183875–184,183) – – – Low [73]
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0226 adjuvant, reflecting most probably the differential in-
nate immune responses induced by each adjuvant [81].
On the other hand, immunization with cocktails up to 47
antigens in a DNA priming and vaccinia virus-boosting re-
gime, allowed the identification of novel T-cell antigens.
Unfortunately, none of the pigs survived the lethal chal-
lenge (Table 4) albeit some pigs showed a significant re-
duction of virus titers in blood and lymph nodes [73].
Finally, priming pigs with a cocktail of replication defi-
cient adenoviruses encoding 12 ASFV ORFs and boost-
ing with same antigens encoded in MVA, allowed the
confirmation of a collection of antigens as capable of in-
ducing specific T-cell responses and to partially protect
pigs from challenge with OURT88/1 (Table 4). Although
all the animals had to be sacrificed before day 8 after
challenge, three out of six pigs showed delayed onset of
clinical signs as well as reduced viremia. Interestingly,
immunization with a second collection of immuno-
gens provoked the exacerbation of the disease, coin-
ciding with the induction of weaker CD8+ T-cell
responses [38].
As a practical observation, we confirm ASFV in vivo
challenge as the only valid method for evaluating the
protective potential of an experimental vaccine. Lack of
correlates of ASFV protection and protective targets,
precludes assuming the potency of a given vaccine for-
mulation based on the immune response induced.
Although the use of subunit vaccines based in ASFV
fragments overcome most of the risks inherent to LAVs,
their use in the field is far from becoming a reality due to
the low efficacy demonstrated so far. As mentioned above,
lack of profound knowledge of the protection mechanisms
together with the absence of known protective antigens
have complicated the design of efficient subunit vaccines
against ASFV. These are in our understanding the future
directions in research and development:
1- Correlates of protection. Easy vaccines have
already been designed. ASFV is a complex virus
capable of inhibiting the pig immune system by
interfering with multiple pathways. Understanding
ASFV strengths will teach us about its weakness.
Table 4 ASFV subunit vaccines tested in vivo that induced some level of protection
Gene Name Immunization Challenge
strain
Outcome Haplotype Reference
A179L, B407L, B438L, B602L, B646L, Complement (183875–
184,183), CP204L, CP2475L, CP530R, D117L, D339L, DP71L,
E120R, E183L, E199L, EP153R, EP364R, EP402R, F1055L,
F317L, G1211R, G1340L, H108R, I329L, K205R, KP177R, L10L,
M1249L, MGF110-2 L, MGF110-4 L, MGF300-2R, MGF360-11
L, MGF360-15R, MGF360-18R, MGF360-1 L, MGF505-4R,
MGF505-5R, NP1450L, NP419L & O61R
DNA prime +
rVACV boost
Georgia
2007/1
No surviving pigs
Reduced viremia and viral loads in
some tissues
Babraham [73]
B646L, CP204L, CP2475L (p37, p150), CP530R & E183L rAd Georgia
2007/1
Partial protection: 5/9 surviving pigs
versus 1/5 control pigs
Reduced viremia depending on the
adjuvant used
Pigs recover from infection
Authors claim that none of the
immunogens conferred statistically
significant protection
Outbred [71, 81]
A151R, B646L, C129R, CP204L, CP530R, E146L, I215L, I73R,
L8L, M448R, MGF110-4 L & MGF110-5 L
rAd prime +
MVA boost
OUR T88/
1
No surviving pigs
3/6 pigs with reduced and delayed
clinical signs, 5/6 pigs with reduced
viremia
Reduced viral load in some tissues
Outbred [38]
CP2475L & A137R Synthetic
peptides
E70 No surviving pigs
Increased average survival
Reduced mean viral titers
Outbred [72]
CP204L & B646L Synthetic
peptides
E70 No surviving pigs
Increased average survival
Reduced mean viral titers
Outbred [72]
CP204L, E183L & EP402 DNA (as a
fusion with
Ub)
E75 Partial protection: 2/6 surviving pis
Delayed clinical signs and viremia
Pigs recover from the infection
Outbred [89]
CP312R DNA
expression
library
E75 Partial protection: 6/10 surviving
pigs
Reduced virus titers in blood,
shedding and lesions
Pigs recover from the infection
Outbred [91, 94]
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Optimal vaccination should not only enhance
protective responses but also avoid prejudicial
immune responses.
2- Antigen discovery. Both humoral and cellular
responses can be protective. Identifying as many
antigens and/or epitopes from the whole proteome
is absolutely needed. This has to be performed in
parallel with understanding the mechanisms
involved in protection.
3- Antigen delivery. We need to know not only what
to induce and with which antigen, but also how to
deliver it in an efficient manner and at an affordable
price. Vaccinology will dramatically change in the
future with the invention of new expression vectors
that should be approved by the safety agencies.
4- Adjuvants. Little attention is given to the need of
novel and efficient adjuvants to formulate a la carte
vaccines, capable of inducing exclusively what is
desired. Adjuvants could be an essential tool to
achieve this goal.
5- Others. DIVA concept, bait-vaccines and cross-
protection. Subunit vaccines against ASFV will be
DIVA by themselves with many immunodominant
antigens available for differential diagnostics. Cross-
protection however is an issue difficult to tackle
today since we need to identify first the mecha-
nisms and the antigens involved. Similarly, bait-
vaccines for oral immunization of wild pigs is an
utopia today, at least for ASF-subunit vaccines, al-
beit it has been recently proposed to experimentally
immunize wild boars with a naturally attenuated
ASFV strain [41]. We should first identify the anti-
gens to incorporate, and then know how to formu-
late them in order to afford significant protection
against ASF. We are not close of having a subunit
vaccine, but if we do not invest in research today,
they will never become a reality.
Conclusions
ASFV vaccines are closer than they appear. On one hand,
several experimental prototypes based on LAVs are ma-
ture enough to be transferred to the private sector for
registration and field trials. International agencies, govern-
ments, industry and academy should join together to dis-
cuss the opportunity of their implementation in very
specific scenarios, taking into account the benefits versus
the prejudices that the new LAVs can provide and the dif-
ferent sensitivity for the ASF problem around the globe.
Parallel efforts should be made in research and devel-
opment of more efficacious and safer subunit vaccines.
Today far from the reality, achieving protection levels
similar to those afforded by LAVs will be challenging.
Complex formulations using multiple ASFV antigens or
antigen fragments, adjuvants and expression vectors can
be envisioned as the future choice, based on knowledge
and scientific evidence.
ASF is a global problem that we were incapable of
stopping. We should learn from our mistakes and find
global solutions.
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